WGS of Basal Cell Carcinoma of skin reveals distinct mutational landscape and the role of HIPPO-YAP pathway in disease progression

被引：0
|
作者：
Nikolaev, Sergey [1 ]
Yurchenko, Andrey [2 ]
Rajabi, Fatemeh [2 ]
Gunbin, Konstantin [2 ]
Pop, Oltin-Tiberiu [3 ]
Padioleau, Ismael [2 ]
Parmentier, Laurent [4 ]
Salomon, Denis [5 ]
Flatz, Lukas [4 ]
机构：
[1] Gustave Roussy Canc Ctr, U981, Villejuif, France
[2] Gustave Roussy Canc Ctr, U981, Villenuif, France
[3] Kantonsspital St Gallen, Inst Immunobiol, St Gallen, Switzerland
[4] Hosp Valais, Dept Dermatol, Sierre, Switzerland
[5] Seujet Clin Dermatol, Geneva, Switzerland
来源：
EUROPEAN JOURNAL OF HUMAN GENETICS | 2023年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
C24.1
引用
收藏
页码：64 / 64
页数：1
相关论文
共 28 条
  • [21] RETRACTION: Downregulation of MicroRNA-130a Inhibits Oral Squamous Cell Carcinoma Proliferation and Metastasis via the Hippo-YAP Pathway (Retraction of Vol 13, Pg 4829, 2021)
    Peng, Y.
    Hu, S.
    Zhang, K.
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8005 - 8005
  • [22] Landscape of brain myeloid cell transcriptome along the spatiotemporal progression of Alzheimer's disease reveals distinct sequential responses to Aβ and tau
    Wachter, Astrid
    Woodbury, Maya E.
    Lombardo, Sylvia
    Abdourahman, Aicha
    Wuest, Carolin
    Mcglame, Emily
    Pastika, Timothy
    Tamm, Joseph
    Romanul, Nandini
    Yanamandra, Kiran
    Bennett, Rachel
    Lin, Gen
    Kwon, Taekyung
    Liao, Fan
    Klein, Corinna
    Grinberg, Yelena
    Jaisa-aad, Methasit
    Li, Huan
    Frosch, Matthew. P.
    Kummer, Markus P.
    Das, Sudeshna
    Dellovade, Tammy
    Karran, Eric H.
    Langlois, Xavier
    Ried, Janina S.
    Serrano-Pozo, Alberto
    Talanian, Robert V.
    Biber, Knut
    Hyman, Bradley T.
    ACTA NEUROPATHOLOGICA, 2024, 147 (01)
  • [23] Landscape of brain myeloid cell transcriptome along the spatiotemporal progression of Alzheimer’s disease reveals distinct sequential responses to Aβ and tau
    Astrid Wachter
    Maya E. Woodbury
    Sylvia Lombardo
    Aicha Abdourahman
    Carolin Wuest
    Emily McGlame
    Timothy Pastika
    Joseph Tamm
    Nandini Romanul
    Kiran Yanamandra
    Rachel Bennett
    Gen Lin
    Taekyung Kwon
    Fan Liao
    Corinna Klein
    Yelena Grinberg
    Methasit Jaisa-aad
    Huan Li
    Matthew. P. Frosch
    Markus P. Kummer
    Sudeshna Das
    Tammy Dellovade
    Eric H. Karran
    Xavier Langlois
    Janina S. Ried
    Alberto Serrano-Pozo
    Robert V. Talanian
    Knut Biber
    Bradley T. Hyman
    Acta Neuropathologica, 2024, 147
  • [24] RETRACTED: Downregulation of MicroRNA-130a Inhibits Oral Squamous Cell Carcinoma Proliferation and Metastasis via the Hippo-YAP Pathway (Retracted article. See vol. 13, pg. 8005, 2021)
    Peng, Yiran
    Hu, Shoushan
    Zhang, Kun
    Wang, Yuru
    Rouzi, Maierdanjiang
    Zhou, Dan
    Yang, Ran
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 4829 - 4840
  • [25] Exploring the Role of Symptom Diversity in Facial Basal Cell Carcinoma: Key Insights into Preoperative Quality of Life and Disease Progression
    Stundys, Domantas
    Kucinskaite, Alvija
    Gervickaite, Simona
    Grigaitiene, Jurate
    Tutkuviene, Janina
    Jancoriene, Ligita
    CANCERS, 2025, 17 (01)
  • [26] N6-methyladenosine-modified DBT alleviates lipid accumulation and inhibits tumor progression in clear cell renal cell carcinoma through the ANXA2/YAP axis-regulated Hippo pathway
    Miao, Daojia
    Wang, Qi
    Shi, Jian
    Lv, Qingyang
    Tan, Diaoyi
    Zhao, Chuanyi
    Xiong, Zhiyong
    Zhang, Xiaoping
    CANCER COMMUNICATIONS, 2023, 43 (04) : 480 - 502
  • [27] Phase II study of cemiplimab, a human monoclonal anti-PD-1, in patients with advanced basal cell carcinoma (BCC) who experienced progression of disease on, or were intolerant of prior hedgehog pathway inhibitor (HHI) therapy
    Lewis, K. D.
    Fury, M. G.
    Stankevich, E.
    Mathias, M.
    Mohan, K. K.
    Li, S.
    Nunnink, K.
    Perry, C.
    Narwal, A.
    ANNALS OF ONCOLOGY, 2018, 29 : 440 - 440
  • [28] Phase-2-Study of Cemiplimab, a human monoclonal PD-1 Antibody, in Patients with advanced Basal Cell Carcinoma (BCC) who have developed Disease Progression or intolerance with previous Hedgehog Signaling Pathway Inhibitor (HHI) Therapy
    Lewis, K.
    Fury, M.
    Stankevich, E.
    Mathias, M.
    Mohan, K.
    Li, S.
    Nunnink, K.
    Perry, C.
    Narwal, A.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 40 - 40
123